The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Early Photocoagulation for Diabetic Retinopathy
(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38011-7 · Cited by 1,259
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Self-citationRosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
Preliminary Report on Effects of Photocoagulation Therapy
(1976) · American Journal of Ophthalmology · doi:10.1016/0002-9394(76)90292-0 · Cited by 723
Cited by
Diabetic retinopathy: current understanding, mechanisms, and treatment strategies
Duh, E. J., Sun, J. K., & Stitt, A. W. (2017) · JCI Insight · doi:10.1172/jci.insight.93751 · Cited by 1,057
Management of Diabetic Retinopathy: A Systematic Review
Mohamed, Q., Gillies, M. C., & Wong, T. Y. (2007) · JAMA · doi:10.1001/jama.298.8.902 · Cited by 891
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Pharmacokinetics of Intravitreal Bevacizumab (Avastin)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.01.017 · Cited by 683
Regulation of retinal blood flow in health and disease
Pournaras, C. J., Rungger-Brändle, E., Riva, C. E., Hardarson, S. H., & Stefansson, E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.02.002 · Cited by 618
Kern, T. S. (2007) · Journal of Diabetes Research · doi:10.1155/2007/95103 · Cited by 614
Pharmacokinetics of Intravitreal Ranibizumab (Lucentis)
Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., Ezzat, M. K., & Singh, R. J. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.012 · Cited by 541
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, B. E. K., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 515
Pathophysiology of Diabetic Retinopathy
Tarr, J. M., Kaul, K., Chopra, M., Kohner, E. M., & Chibber, R. (2013) · ISRN Ophthalmology · doi:10.1155/2013/343560 · Cited by 455
Arevalo, J. F., Maia, M., Flynn, H. W., Saravia, M., Avery, R. L., Wu, L., Farah, M. E., Pieramici, D. J., Berrocal, M. H., & Sanchez, J. G. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.127142 · Cited by 411
Self-citationAvery, R. L., Castellarin, A. A., Steinle, N. C., Dhoot, D. S., Pieramici, D. J., See, R., Couvillion, S., Nasir, M. A., Rabena, M. D., Le, K., et al. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305252 · Cited by 382
Self-citationOcular complications of diabetes mellitus
Sayin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.92 · Cited by 358
Sato, T., Wada, K., Arahori, H., Kuno, N., Imoto, K., Iwahashi-Shima, C., & Kusaka, S. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.07.005 · Cited by 327
Immunological mechanisms in the pathogenesis of diabetic retinopathy
Adamis, A. P., & Berman, A. J. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0111-x · Cited by 322
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 304
Neutrophil extracellular traps target senescent vasculature for tissue remodeling in retinopathy
Binet, F., Cagnone, G., Crespo-Garcia, S., Hata, M., Neault, M., Dejda, A., Wilson, A. M., Buscarlet, M., Mawambo, G. T., Howard, J. P., et al. (2020) · Science · doi:10.1126/science.aay5356 · Cited by 283
“In DR, spontaneous regression of neovascularization (NV) has been reported (13, 14), albeit less frequently given that upon diagnosis, standard of care calls for immediate pan-retinal photocoagulation (15), anti–vascular endothelial growth factor (anti-VEGF) therapy (16), or other treatments such that physiological re…”
BackgroundAnti-vascular endothelial growth factor therapy for ocular neovascular disease
Andreoli, C. M., & Miller, J. W. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282f0ca54 · Cited by 274
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272
Diabetic retinopathy and systemic vascular complications
Cheung, N., & Wong, T. Y. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.12.001 · Cited by 269
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3148 · Cited by 269
Sohn, H. J., Han, D. H., Kim, I. T., Oh, I. K., Kim, K. H., Lee, D. Y., & Nam, D. H. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.03.033 · Cited by 265
A review of anti-VEGF agents for proliferative diabetic retinopathy
Osaadon, P., Fagan, X. J., Lifshitz, T., & Levy, J. (2014) · Eye · doi:10.1038/eye.2014.13 · Cited by 265
Molecular mechanism of VEGF and its role in pathological angiogenesis
Ahmad, A., & Nawaz, M. I. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30344 · Cited by 260
Brantley, M. A., Fang, A. M., King, J. M., Tewari, A., Kymes, S. M., & Shiels, A. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.008 · Cited by 201
Obeid, A., Su, D., Patel, S. N., Uhr, J. H., Borkar, D., Gao, X., Fineman, M. S., Regillo, C. D., Maguire, J. I., Garg, S. J., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.027 · Cited by 180
Hypoxia-inducible factors and diabetes
Gunton, J. E. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137556 · Cited by 159
Grishanin, R., Vuillemenot, B., Sharma, P., Keravala, A., Greengard, J., Gelfman, C., Blumenkrantz, M., Lawrence, M., Hu, W., Kiss, S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.003 · Cited by 127
“Degeneration of the macula, which plays a critical role in detailed central vision, leads to blurred or distorted areas within the central visual field.(1,2) Approximately 10% to 20% of patients with AMD develop abnormal blood vessel formation in the choroid layer area under the macula.”
BackgroundComprehensive review of the effects of diabetes on ocular health
Skarbez, K., Priestley, Y., Hoepf, M., & Koevary, S. B. (2010) · Expert Review of Ophthalmology · doi:10.1586/eop.10.44 · Cited by 117
Mitchell, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.585394 · Cited by 102
“, 2008 (PIER) Multicenter, randomized, double-masked, controlled trial (1-year) 184 Sham (63) 0.”
Maguire, M. G., Daniel, E., Shah, A. R., Grunwald, J. E., Hagstrom, S. A., Avery, R. L., Huang, J., Martin, R. W., Roth, D. B., Castellarin, A. A., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.017 · Cited by 93
Self-citationMicrovascular complications and diabetic retinopathy: recent advances and future implications
Barot, M., Gokulgandhi, M. R., Patel, S., & Mitra, A. K. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.206 · Cited by 92
Oxygen Sensing in Retinal Health and Disease
Lange, C. A. K., & Bainbridge, J. W. B. (2012) · Ophthalmologica · doi:10.1159/000331418 · Cited by 86
Mini drug pump for ophthalmic use
Saati, S., Lo, R., Li, P.-Y., Meng, E., Varma, R., & Humayun, M. S. (2010) · Current Eye Research · doi:10.3109/02713680903521936 · Cited by 77
Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro
O'Neill, E. C., Qin, Q., Van Bergen, N. J., Connell, P. P., Vasudevan, S., Coote, M. A., Trounce, I. A., Wong, T. T. L., & Crowston, J. G. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5669 · Cited by 73
Acute Anterior Uveitis Following Intravitreal Injection of Bevacizumab
Mozayan, A., & Farah, S. (2013) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20121221-08 · Cited by 22
Van Geest, R. J., Lesnik-Oberstein, S. Y., Tan, H. S., Mura, M., Goldschmeding, R., Van Noorden, C. J. F., Klaassen, I., & Schlingemann, R. O. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-301005 · Cited by 141
Metadata
- Authors
- Avery, R. L., Pearlman, J., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2006-10
- Volume
- 113
- Issue
- 10
- Pages
- 1695-1705.e6
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2122595579
- Cited by
- 799
- References
- 23
- FWCI
- 66.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.